UNSPSC 51292803: Doxepin

This classification denotes a tricyclic antidepressant, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5ASJ6HUZ7D. European Medicines Agency schedules Doxepin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06387MIG. Doxepin generally arises in the molecular formula C19H21NO.

The term DOXEPIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, no. 10, 1968, list 8.) DOXEPIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule doxepin under HS 29329985 and SITC 51569. As of Q4 2014, DOXEPIN remains the US FDA Preferred Term for this commodity. Doxepin bears US NLM identifiers UMLS ID C0013085 and NCI Concept Code C65475. SMILES: CN(C)CCC=C1C2=CC=CC=C2COC3=CC=CC=C31.

UNSPSC 51292803 Doxepin (Commodity) encompasses pharmaceutical products procured by state and local health agencies, though the recent solicitations tagged to this code show limited direct activity in doxepin itself. Instead, state and local buyers are sourcing naloxone, safe drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products through competitive bidding and cooperative purchasing arrangements. The issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, representing Minnesota, Oregon, and other participants). Vendors must meet standard compliance requirements—E-Verify authorization, drug-free workplace certification, current Good Manufacturing Practices (cGMP), and Drug Supply Chain Security Act (DSCSA) compliance—and carry insurance including workers' compensation, commercial general liability, and professional liability. Supply relationships flow through authorized wholesalers rather than direct-to-agency delivery in most cases.

Recent activity concentrates in Florida, Texas, and Minnesota. Seminole County posted IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building; the bid closed July 26, 2023 (note: the solicitation posting date and closure date in the source appear inconsistent). The Texas HHS Commission issued RFI HHS0017013 in April 2026 to explore direct-to-manufacturer prescription programs and vendor capabilities for negotiated net pricing models, representing an exploratory phase before formal RFP release. MMCAP released RFP S1070000015802 in January 2026 seeking manufacturers of generic pharmaceuticals and OTC products with an RFP deadline of March 26, 2026 and contract effectiveness of July 1, 2026; evaluation weighted price competitiveness at 75 percent and required 3 percent administrative fees on all purchases. The code shows modest recent solicitation frequency; most activity appears concentrated in cooperative purchasing and health department procurement rather than widespread state or local uptake of doxepin specifically.